Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD
August 9th 2023Discussion centered around real-world data following the approval of ruxolitinib as a treatment option for patients with chronic GvHD as well as discussing treatment selection for patients with chronic GvHD, with special consideration for treatment sequencing.
Nationwide Initiative Aims to Address Disparities in Early-Phase Cancer Clinical Trials
To expand access to cancer care and research, Stand Up To Cancer® has launched a 4-team initiative across the United States designed to fill in these gaps in care and remove barriers to entry.
Erdafitinib Elicits Responses in High- and Intermediate-Risk NMIBC Harboring FGFR3/2 Alterations
March 22nd 2023Siamak Daneshmand, MD, shed light on the phase 2 THOR-2 study evaluating different cohorts of patients with recurrent NMIBC, key findings from cohorts 2 and 3, and how ongoing research seeks to move the needle forward with novel drug delivery methods.
Pembrolizumab Data Highlight Potential for Adjuvant Immunotherapy in RCC
Christopher W. Ryan, MD, discusses the role of adjuvant pembrolizumab in renal cell carcinoma, the use of immunotherapy-based combinations in the frontline setting for metastatic renal cell carcinoma, and key data presented at the 2023 Genitourinary Cancers Symposium in bladder cancer and prostate cancer.
Combinations Gain Momentum as First-Line Treatments for Unresectable Hepatocellular Carcinoma
May 25th 2022A panel of hepatobiliary tumor experts discuss several pivotal phase 3 clinical trials examining combination approaches that have expanded or are anticipated to expand the treatment armamentarium for treatment-naïve patients with unresectable hepatocellular carcinoma.
Heinz-Josef Lenz, MD, discusses the safety and efficacy of nivolumab plus standard of care in patients with metastatic colorectal cancer, shares additional insight from the CheckMate-9X8 trial, and alludes to next steps with further exploring the regimen in specific subsets who appear to derive benefit from this approach.
Nivolumab Plus mFOLFOX6 and Bevacizumab Misses PFS End Point in mCRC
The addition of nivolumab to mFOLFOX6 and bevacizumab failed to demonstrate a statistically significant improvement in progression-free survival vs mFOLFOX6 and bevacizumab alone in previously untreated patients with metastatic colorectal cancer, according to findings from the phase 2/3 CheckMate 9X8 trial.
Immunotherapy Approvals Overcome Years of Stagnation in GI Cancers
December 28th 2021Syma Iqbal, MD, shares the main highlights from an IPC meeting, which centered on the evolving landscapes and importance of implementing best practices for patients with hepatobiliary cancers, locally advanced and advanced pancreatic cancer, advanced gastric/gastroesophageal junction cancer, and metastatic colorectal cancer.
Sequencing Strategies May Shift With Emerging Options in GI Malignancies
December 24th 2021With the rapid uptake of novel therapies, including immunotherapy and targeted therapy, shifts in treatment strategies are anticipated in hepatobiliary cancers, locally advanced and advanced pancreatic cancer, gastric/gastroesophageal junction cancers, and metastatic colorectal cancer.
African Ancestry Is Linked With Higher Prostate Cancer Risk Vs European Ancestry
August 2nd 2021Germline variation could play a role in racial disparities related to prostate cancer risk, with individuals of African descent having a higher mean genetic risk score compared with men of European ancestry.